Scribd Logo
Upload

Welcome to Scribd!

  • 2K views

    Rhogam Medication Template

    Uploaded by

    AA DD
    Rhogam is a medication given to prevent Rh (D) sensitization in Rh (D) negative pregnant patients exposed to Rh (D) positive blood. It prevents the production of Rh (D) antibodies which can cause hemolytic disease in future pregnancies. It is administered intramuscularly within 72 hours of delivery if the baby is Rh (D) positive or if the baby's blood type is uncertain. Rhogam is also used to increase platelet counts in patients with immune thrombocytopenic purpura. Potential side effects include dizziness, headache, and pain at the injection site. Patients should be monitored for signs of intravascular hemolysis and anemia.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    Rhogam Medication Template

    Uploaded by

    AA DD
    2K views1 page
    Rhogam is a medication given to prevent Rh (D) sensitization in Rh (D) negative pregnant patients exposed to Rh (D) positive blood. It prevents the production of Rh (D) antibodies which can cause hemolytic disease in future pregnancies. It is administered intramuscularly within 72 hours of delivery if the baby is Rh (D) positive or if the baby's blood type is uncertain. Rhogam is also used to increase platelet counts in patients with immune thrombocytopenic purpura. Potential side effects include dizziness, headache, and pain at the injection site. Patients should be monitored for signs of intravascular hemolysis and anemia.

    Original Description:

    Ati Medication template

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Read this document in other languages

    Did you find this document useful?

    Is this content inappropriate?

    Rhogam is a medication given to prevent Rh (D) sensitization in Rh (D) negative pregnant patients exposed to Rh (D) positive blood. It prevents the production of Rh (D) antibodies which can cause hemolytic disease in future pregnancies. It is administered intramuscularly within 72 hours of delivery if the baby is Rh (D) positive or if the baby's blood type is uncertain. Rhogam is also used to increase platelet counts in patients with immune thrombocytopenic purpura. Potential side effects include dizziness, headache, and pain at the injection site. Patients should be monitored for signs of intravascular hemolysis and anemia.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    2K views1 page

    Rhogam Medication Template

    Uploaded by

    AA DD
    Rhogam is a medication given to prevent Rh (D) sensitization in Rh (D) negative pregnant patients exposed to Rh (D) positive blood. It prevents the production of Rh (D) antibodies which can cause hemolytic disease in future pregnancies. It is administered intramuscularly within 72 hours of delivery if the baby is Rh (D) positive or if the baby's blood type is uncertain. Rhogam is also used to increase platelet counts in patients with immune thrombocytopenic purpura. Potential side effects include dizziness, headache, and pain at the injection site. Patients should be monitored for signs of intravascular hemolysis and anemia.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    of 1

    ACTIVE LEARNING TEMPLATE: Medication

    STUDENT NAME______________________________________
    Rhogam
    MEDICATION___________________________________________________________________________ REVIEW MODULE CHAPTER____________

    CATEGORY CLASS_______________________________________________________________________

    PURPOSE OF MEDICATION

    Expected Pharmacological Action Therapeutic Use


    Prevent production of Rh (D) antibodies in Prevention of antibody response and
    Rh (D) negative patients who were exposed hemolytic disease of the newborn in future
    to Rh (D) positive blood. Increase platelet pregnancies of women who have conceived
    counts in patients with ITP. a Rh (D) positive fetus

    Complications Medication Administration


    Medication Administration dizziness, headache, Following Delivery IM (Adults): Hyper
    hypertension, hypotension, diarrhea, nausea, vomiting, RHO S/D Full Dose, RhoGAM—1 vial
    acute renal failure, pain at injection site, fever IM IV standard dose (300 mcg) within 72 hr
    of delivery. BeforeDeliveryIM (Adults):
    Hyper RHO S/D Full Dose,
    RhoGAM—1 vial standard dose (300
    mcg)at 26 – 28 wk.

    Contraindications/Precautions
    Prior hypersensitivity reaction to human immune globulin,
    Rh (D) or DU positive patients P: ITP patients with
    pre-existing anemia Nursing Interventions
    Interactions Decreased antibody response to some live Assess vital signs
    Monitor for s/s of intravascular hemolysis-monitor platelet
    virus vaccines such as MMR Client Education count-monitor CBC, hemoglobin. Type and crossmatch of mother
    and newborn's cord blood must be performed to determine need
    for medication. In Pregnancy:Type and crossmatch of mother
    and newborn’s cord blood must be performed to determine
    need for medication. Mother must be Rho (D)-negative and
    Du-negative. Infant must be Rho(D)-positive. If there is doubt
    regarding infant’s blood type or if father is Rho
    Interactions (D)-positive,medication should be given. An infant born to a
    woman treated with Rho(D) immune globulin antepartum may
    have a weakly positive direct Coombs’ test result on cord or
    Liver virus vaccines infant blood. ITP:Monitor platelet counts, RBC counts,
    hemoglobin, and reticulocyte levels todetermine effectiveness of
    therapy

    Client Education
    eduacte client about the signs
    and symptoms of intravascular
    Evaluation of Medication Effectiveness hemolysis(IVH) (back pain,
    Prevention of erythroblastosis fetalis in the future Rh (D) shaking chills, fever,
    positive infants. Prevention of Rh (D) sensitization hemoglobinuria), anemia,
    following incompatible transfusion. Decreased bleeding andrenal insufficiency) and that
    episodes in patients with ITP. they should be reported to a
    healthcare person

    ACTIVE LEARNING TEMPLATES

    You might also like